



ASX Code: SIP

31 May 2010

ASX ANNOUNCEMENT

Sigma grants Aspen Pharmacare access to due diligence

On 21 May 2010, Sigma announced that it had received a non-binding, indicative and conditional proposal to acquire all of the issued share capital of Sigma for an indicative price of \$0.60 per share under a scheme of arrangement or other whole of business transaction ("Indicative Proposal"). On 24 May 2010, Sigma confirmed that the party referred to in that announcement is Aspen Pharmacare Holdings Limited.

Sigma and Aspen have now entered into a confidentiality agreement pursuant to which Aspen will be provided with due diligence information on Sigma.

As part of that agreement, Aspen has been granted limited exclusivity by Sigma for the next four weeks, during which period Sigma has agreed not to solicit rival bids for another whole of business transaction for Sigma, or to enter into contracts in relation to asset sales. However, Sigma is continuing the previously foreshadowed asset sale program.

Sigma continues to recommend that shareholders take no action at this time in relation to the Indicative Proposal. The due diligence process being undertaken by Aspen may or may not result in a formal proposal or a recommendation by the Board.

Sue Morgan-Dethick
General Counsel & Company Secretary

SIGMA PHARMACEUTICALS LIMITED
ABN 15 088 417 403

Locked Bag 268 (96 Merrindale Drive) Croydon Victoria 3136 Australia
Telephone: (+61-3) 03-9839 2800 Facsimile: (+61-3) 03-9839 2811